Highly efficient synthesis of 1- and 5-substituted 1H-tetrazoles using chitosan derived magnetic ionic liquid as a recyclable biopolymer-supported catalyst
作者:Ali Khalafi-Nezhad、Somayeh Mohammadi
DOI:10.1039/c3ra23107k
日期:——
A general method for the efficient synthesis of 1- and 5-substituted1H-tetrazoles from nitriles and amines is described using chitosan supported magnetic ionic liquid nanoparticles (CSMIL) as a novel heterogeneous catalyst. The application of this catalyst allows the synthesis of a variety of tetrazoles in high yields at low temperature. This new magnetic catalyst has been prepared from chitosan (the
One-Pot Synthesis of Multisubstituted 2-Aminoquinolines from Annulation of 1-Aryl Tetrazoles with Internal Alkynes via Double C–H Activation and Denitrogenation
作者:Lei Zhang、Liyao Zheng、Biao Guo、Ruimao Hua
DOI:10.1021/jo502192b
日期:2014.12.5
An efficient, one-pot synthesis of multisubstituted 2-aminoquinolines from 1-aryl tetrazoles and internal alkynes has been developed. The reaction involves cyclization of 1-aryl tetrazoles with internal alkynes via rhodium(III)-catalyzed double C–H activation and copper(II)-mediated denitrogenation.
Synthetic manifestation of nitro substituted tetrazole-N-(hetero)aryl derivatives and energetic studies
作者:Nagarjuna Kommu、M. Balaraju、Vikas D. Ghule、Akhila K. Sahoo
DOI:10.1039/c6ta10621h
日期:——
substituted tetrazole-N-aryl/heteroaryl derivatives is discussed here. The energetic functional groups –NO2, –NHNO2 and –N3 are reliably inserted into the molecular backbone, making the tetrazole-N-aryl derivatives highly energetic and insensitive to heat and impact. For example, the tetrazole derivatives 7 and 8, bearing a –NO2 or a –NHNO2 group, exhibit energetic properties close to RDX, but with enhanced
[EN] PROTEIN KINASE C INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE C ET UTILISATIONS DE CEUX-CI
申请人:RIGEL PHARMACEUTICALS INC
公开号:WO2014089112A1
公开(公告)日:2014-06-12
This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.